Nanopatch Immunisation Against Pandemic Influenza: Improved Immune Responses At A Reduced Dose.
Funder
National Health and Medical Research Council
Funding Amount
$511,294.00
Summary
Development of a new way to vaccinate against influenza that will make standard vaccines 100 times more potent than conventional syringe injection. The Nanopatch is made from a silicon wafer, bristling with micro-nanoscale spikes. It painlessly deposits vaccine under the skin surface. Experiments in mice show that even a small vaccine payload delivered to the skin generates good immune responses. The Nanopatch vaccination system is expected to be ready for clinical trials within a few years.
Antibodies are made by B-cells and are essential for a functional immune system. B cells circulate in the body, and, when they encounter an invader, they mature into antibody-producing cells (ASC). A small proportion of the cells become “memory” cells with the potential to become ASC should the same infection occur in the future. This is the basis of vaccination. This program aims to understand how a B cell changes into an ASC. We aim eventually to be able to improve vaccines and understand dise ....Antibodies are made by B-cells and are essential for a functional immune system. B cells circulate in the body, and, when they encounter an invader, they mature into antibody-producing cells (ASC). A small proportion of the cells become “memory” cells with the potential to become ASC should the same infection occur in the future. This is the basis of vaccination. This program aims to understand how a B cell changes into an ASC. We aim eventually to be able to improve vaccines and understand diseases such as allergy, lupus, arthritis and leukaemia to develop novel therapies.Read moreRead less